US Supreme Court rejects Vanda Pharmaceuticals' bid to revive Hetlioz patents, avoiding addressing when a patent can be invalidated.

Vanda Pharmaceuticals' bid to revive patents for its sleep-disorder drug Hetlioz, previously declared invalid in a dispute with generic drugmakers Teva and Apotex, has been rejected by the US Supreme Court. The court turned away Vanda's appeal of a lower court's ruling against the company, which had sued the generic drugmakers in 2018 for patent infringement. This decision marks the Supreme Court's avoidance of addressing when a patent can be invalidated.